Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 2,601 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.16, for a total transaction of $42,032.16. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of Momenta Pharmaceuticals stock traded up $0.45 on Tuesday, hitting $16.45. 871,694 shares of the company traded hands, compared to its average volume of 524,335. The stock has a market capitalization of $1.62 billion, a P/E ratio of -8.10 and a beta of 2.07. Momenta Pharmaceuticals, Inc. has a 52 week low of $9.51 and a 52 week high of $16.90. The business has a 50-day simple moving average of $14.24 and a 200 day simple moving average of $12.84.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.09). The company had revenue of $6.40 million for the quarter, compared to the consensus estimate of $5.24 million. Momenta Pharmaceuticals had a negative net margin of 361.66% and a negative return on equity of 59.82%. The company’s quarterly revenue was down 57.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.65) EPS. As a group, research analysts anticipate that Momenta Pharmaceuticals, Inc. will post -2.59 earnings per share for the current year.
Several equities research analysts have recently issued reports on the stock. SunTrust Banks assumed coverage on shares of Momenta Pharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $29.00 price objective on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $29.00 price objective on shares of Momenta Pharmaceuticals in a research report on Thursday, October 24th. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 31st. Wells Fargo & Co assumed coverage on shares of Momenta Pharmaceuticals in a research report on Wednesday, November 6th. They set an “outperform” rating on the stock. Finally, ValuEngine upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $23.45.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
Featured Story: What are the disadvantages of after-hours trading?
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
